Work

Who and when should we screen for prostate cancer? Interviews with key opinion leaders

Year: 2015

Type: editorial

Abstract: Prostate cancer screening using prostate-specific antigen (PSA) is highly controversial. In this Q & A, Guest Editors for BMC Medicine's 'Spotlight on Prostate Cancer' article collection, Sigrid Carlsson and Andrew Vickers, invite some of the world's key opinion leaders to discuss who, and when, to screen for prostate cancer. In response to the points of view from the invited experts, the Guest Editors summarize the experts' views and give their own personal opinions on PSA screening.

Source: BMC Medicine

DOI: 10.1186/s12916-015-0526-x

Authors: Sigrid Carlsson, Michael Leapman, Peter Carroll, Fritz Schröder, Peter C. Albertsen, Dragan Ilic, Michael Barry, Dominick L. Frosch, Andrew Vickers

Institutions: Memorial Sloan Kettering Cancer Center, University of California, San Francisco, Erasmus MC, UConn Health, The Alfred Hospital, Monash University, Informed Medical Decisions Foundation, University of California, Los Angeles, Gordon and Betty Moore Foundation

Language: English

Topic: Prostate Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,190

Funders: Memorial Sloan-Kettering Cancer Center, AFA Försäkring, National Cancer Institute

Awards: G2051006376, G289723095, G4102770861, Cancer Center Support Grant

OpenAlex ID: W2181223509

Cites: 80

Cited by: 9

Related to: 10